A significant percentage of human immunodeficiency virus type 1 (HIV-1)–infected persons
treated with highly active antiretroviral therapy (HAART) will develop plasma HIV-1–specific …

Background: Human T-lymphotropic virus (HTLV)-I and HTLV-II cause chronic human
retroviral infections, but few studies have examined the impact of either virus on survival …

HIV-individuals are at risk for human T-lymphotropic virus (HTLV) coinfection and
neurological diseases. Little is known about the impact of HAART among coinfected …

Data on T-cell subsets from 89 human T-cell lymphotropic virus-I (HTLV-I) carriers and 25
seronegative people were analyzed to identify differences in T-cell subset values among …

Using data obtained in national surveys of human T-lymphotropic virus type I (HTLV-I)-
associated myelopathy/tropical spastic paraparesis (HAM/TSP) conducted in Japan in 1987 …

The correlation between virus load and specific cytotoxic T–lymphocyte (CTL) frequency
during the chronic phase in human immunodeficiency virus type 1 (HIV–1) infection has …

The impact of highly active antiretroviral treatment (HAART) on anti-human
immunodeficiency virus (HIV) cytotoxic T lymphocytes (CTL) was studied in 17 patients with …

Human immunodeficiency virus (HIV)–specific CD4+ and CD8+ T cell responses were
evaluated prospectively in a large cohort of subjects with HIV primary infection via long-term …

Important clinical effects of HTLV/HIV co-infection include the higher rates of myelopathy and
other neurological disorders and the poor predicative value of CD4+ cell counts as a …

OBJECTIVE: To evaluate HIV-1 DNA load in PBLs and monocytes from both long-term
HAART-treated and antiretroviral naïve HIV-1 infected patients. METHODS: Cross-sectional …